Guidant gets FDA panel backing to use HF (heart failure) device more widely
This article was originally published in Clinica
A US FDA advisory committee has proposed that the agency expand the indications for Guidant's cardiac resynchronisation therapy defibrillators (CRT-Ds), a move that would make the product line available to thousands of additional heart failure (HF) patients.
You may also be interested in...
ASTM International is proposing a new standard that will provide a cleaning agent formula for removing dried blood from stainless steel medical devices.
Executive appointments at MyoKardia, Scancell Holdings and Sutro Biopharma
The merger between Mylan and Pfizer’s Upjohn unit finally concluded on 16 November 2020, giving Viatris the go ahead for business. The newly-established company has announced receiving tentative approval for its 10mg pediatric dolutegravir tablets from the FDA under the PEPFAR program.